Post ACS Secondary Prevention Optimization Tool
Clinical review checklist
Review secondary-prevention domains after acute coronary syndrome.
How to use the findings
Use the checklist to identify treatment and care-process items that may need discussion. Confirm each decision against the patient’s ACS presentation, revascularization status, time since event, renal function, potassium, blood pressure, bleeding risk, contraindications, medication tolerance, and preferences.
- Antithrombotic treatment requires an individualized plan, particularly when oral anticoagulation or high bleeding risk is present.
- After ACS, high-intensity statin therapy is recommended when tolerated. Consider nonstatin treatment according to LDL-C, existing therapy, and the applicable guideline.
- RAAS inhibitors and MRAs depend on clinical indications, renal function, potassium, and contraindications.
- Cardiac rehabilitation and smoking cessation support are important components of comprehensive secondary prevention.
Clinical references
Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025.
doi:10.1016/j.jacc.2024.11.009
Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.